PERFORMANCE UNIT AGREEMENTPerformance Unit Agreement • August 9th, 2007 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
On this __ day of _______________ (the “Grant Date”), Amgen Inc., a Delaware corporation (the “Company”), pursuant to its Performance Award Program (the “Program”) which implements the Amended and Restated 1991 Equity Incentive Plan (the “Plan”), has granted to you, the grantee named above, _____________ performance units (the “Units”) on the terms and conditions set forth in this Performance Unit Agreement (this “Agreement”), the Plan, the Program and the Resolutions (as defined below). Capitalized terms not defined herein shall have the meanings assigned to such terms in the Program.
PURCHASE AGREEMENTRegistration Rights Agreement • August 9th, 2007 • Amgen Inc • Biological products, (no disgnostic substances) • New York
AMENDMENT NO. 13 TO THE SHAREHOLDERS’ AGREEMENT OF KIRIN-AMGEN, INC.Shareholders’ Agreement • August 9th, 2007 • Amgen Inc • Biological products, (no disgnostic substances) • California
PURCHASE AGREEMENT Dated May 24, 2007 between AMGEN INC. and MORGAN STANLEY & CO. INCORPORATED and MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED and THE INITIAL PURCHASERS NAMED IN SCHEDULE A HEREOFPurchase Agreement • August 9th, 2007 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several purchasers named in Schedule A hereto (the “Initial Purchasers”) $2,000,000,000 aggregate principal amount of its Senior Floating Rate Notes due 2008 (the “Floating Rate Notes”), $1,100,000,000 aggregate principal amount of its 5.85% Senior Notes due 2017 (the “2017 Notes”) and $900,000,000 aggregate principal amount of its 6.375% Senior Notes due 2037 (the “2037 Notes” and, together with the Floating Rate Notes and the 2017 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and The Bank of New York, as successor to JPMorgan Chase Bank, N.A., as trustee (the “Trustee”).
